Weisberg EL - Search Results

1

Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma.

Wu H, Wang W, Liu F, Weisberg EL, Tian B, Chen Y, Li B, Wang A, Wang B, Zhao Z, McMillin DW, Hu C, Li H, Wang J, Liang Y, Buhrlage SJ, Liang J, Liu J, Yang G, Brown JR, Treon SP, Mitsiades CS, Griffin JD, Liu Q, Gray NS. Wu H, et al. Among authors: weisberg el. ACS Chem Biol. 2014 May 16;9(5):1086-91. doi: 10.1021/cb4008524. Epub 2014 Mar 17. ACS Chem Biol. 2014. PMID: 24556163 Free PMC article.

2

Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines.

Weisberg E, Griffin JD. Weisberg E, et al. Blood. 2000 Jun 1;95(11):3498-505. Blood. 2000. PMID: 10828035 Free article.

3

ARG tyrosine kinase activity is inhibited by STI571.

Okuda K, Weisberg E, Gilliland DG, Griffin JD. Okuda K, et al. Blood. 2001 Apr 15;97(8):2440-8. doi: 10.1182/blood.v97.8.2440. Blood. 2001. PMID: 11290609 Free article.

4

Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patients.

Weisberg E, Griffin JD. Weisberg E, et al. Drug Resist Updat. 2001 Feb;4(1):22-8. doi: 10.1054/drup.2001.0180. Drug Resist Updat. 2001. PMID: 11512149 Review.

5

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

Weisberg E, Boulton C, Kelly LM, Manley P, Fabbro D, Meyer T, Gilliland DG, Griffin JD. Weisberg E, et al. Cancer Cell. 2002 Jun;1(5):433-43. doi: 10.1016/s1535-6108(02)00069-7. Cancer Cell. 2002. PMID: 12124173 Free article.

6

The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.

Lin B, Podar K, Gupta D, Tai YT, Li S, Weller E, Hideshima T, Lentzsch S, Davies F, Li C, Weisberg E, Schlossman RL, Richardson PG, Griffin JD, Wood J, Munshi NC, Anderson KC. Lin B, et al. Cancer Res. 2002 Sep 1;62(17):5019-26. Cancer Res. 2002. PMID: 12208756

7

Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.

Sattler M, Scheijen B, Weisberg E, Griffin JD. Sattler M, et al. Adv Exp Med Biol. 2003;532:121-40. doi: 10.1007/978-1-4615-0081-0_11. Adv Exp Med Biol. 2003. PMID: 12908554 Review.

8

Resistance to imatinib (Glivec): update on clinical mechanisms.

Weisberg E, Griffin JD. Weisberg E, et al. Drug Resist Updat. 2003 Oct;6(5):231-8. doi: 10.1016/s1368-7646(03)00062-1. Drug Resist Updat. 2003. PMID: 14643293 Review.

9

Aminopeptidase inhibitors inhibit proliferation and induce apoptosis of K562 and STI571-resistant K562 cell lines through the MAPK and GSK-3beta pathways.

Sawafuji K, Miyakawa Y, Weisberg E, Griffin JD, Ikeda Y, Kizaki M. Sawafuji K, et al. Leuk Lymphoma. 2003 Nov;44(11):1987-96. doi: 10.1080/1042819031000122033. Leuk Lymphoma. 2003. PMID: 14738154

10

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

Weisberg E, Manley PW, Breitenstein W, Brüggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, Kung AL, Mestan J, Daley GQ, Callahan L, Catley L, Cavazza C, Azam M, Neuberg D, Wright RD, Gilliland DG, Griffin JD. Weisberg E, et al. Cancer Cell. 2005 Feb;7(2):129-41. doi: 10.1016/j.ccr.2005.01.007. Cancer Cell. 2005. PMID: 15710326 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

117 results

Search Page